, Treatment of steroid-resistant acute graft-vshost disease after allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT563), Transplant Proc, vol.26, issue.6, pp.3114-3120, 1994.
, Treatment of steroid-resistant acute graft-versushost disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants, Bone Marrow Transplant, 1994.
, Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy, Bone Marrow Transplant, vol.10, issue.5, pp.451-456, 1992.
, Use of monoclonal antibodies in vivo as a therapeutic strategy for acute GvHD in matched and mismatched bone marrow transplantation, Transplant Proc Feb, vol.23, issue.1 2, pp.1692-1696, 1991.
, Treatment of corticosteroid resistant acute graftversus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10), Blood Feb, vol.15, issue.754, pp.1017-1040, 1990.
, CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,S, Transplantation, vol.18, issue.4, pp.295-304, 1974.
DOI : 10.1097/00007890-197410000-00001
, Bone-Marrow Transplantation, New England Journal of Medicine, vol.292, issue.17, pp.895-902, 1975.
DOI : 10.1056/NEJM197504242921706
, IBMTR Severity INDEX FOR GRADING ACUTE GRAFT-VERSUS-HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE, British Journal of Haematology, vol.97, issue.4, pp.855-64, 1997.
DOI : 10.1046/j.1365-2141.1997.1112925.x
, The clinical evaluation of chemotherapeutic agents in cancer Evaluation of Chemotherapeutic Agents, pp.199-205, 1949.
, NONMEM User's Guides. NONMEM project group
, Population pharmacokinetic modeling: the importance of informative graphics, Pharmaceutical Research, vol.12, issue.12, pp.1845-55, 1995.
DOI : 10.1023/A:1016215116835
, Guidance for industry -Population pharmacokinetics. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Center for, Biologics Evaluation and Research Feb, 1999.
, A guide for reporting the results of population pharmacokinetic analyses: A Swedish perspective, The AAPS Journal, vol.7, issue.2, p.45, 2005.
DOI : 10.1208/aapsj070245
, Modelling ordered categorical data: recent advances and future challenges, Statistics in Medicine, vol.28, issue.17-18, pp.17-18, 1999.
DOI : 10.1002/(SICI)1097-0258(19990915/30)18:17/18<2191::AID-SIM249>3.0.CO;2-M
, A pharmacokinetic simulation model for ivabradine in healthy volunteers, European Journal of Pharmaceutical Sciences, vol.10, issue.4, pp.285-94, 2000.
DOI : 10.1016/S0928-0987(00)00086-5
, Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.2, pp.171-92, 2001.
DOI : 10.1023/A:1011555016423
, Bayesianly Justifiable and Relevant Frequency Calculations for the Applied Statistician, The Annals of Statistics, vol.12, issue.4, pp.1151-72, 1984.
DOI : 10.1214/aos/1176346785
, Simulation for population pharmacodynamic analysis of doseranging trials: usefulness of the mixture model analysis for detecting nonresponders, Pharmaceutical Research, vol.19, issue.6, pp.909-922, 2002.
DOI : 10.1023/A:1016181505556
, TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE WITH METHYLPREDNISOLONE AND CYCLOSPORINE WITH OR WITHOUT AN ANTI-INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY, Transplantation, vol.60, issue.9, pp.939-981, 1995.
DOI : 10.1097/00007890-199511150-00010
, Inolimomab in Steroid-Refractory Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis and Comparison with Other Interleukin-2 Receptor Antibodies, Transplantation, vol.80, issue.6, pp.782-790, 2005.
DOI : 10.1097/01.TP.0000173995.18826.DE
, Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors, Bone Marrow Transplantation, vol.32, issue.8, pp.777-84, 2003.
DOI : 10.1038/sj.bmt.1704213
, Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia, Biology of Blood and Marrow Transplantation, vol.8, issue.9, pp.477-85, 2002.
DOI : 10.1053/bbmt.2002.v8.pm12374452
, Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation, Clinical Pharmacology & Therapeutics, vol.78, issue.5, pp.486-500, 2005.
DOI : 10.1016/j.clpt.2005.08.009
, NONMEM User's Guide -Part VII. Conditional Estimation Methods
, Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation, British Journal of Clinical Pharmacology, vol.22, issue.special issue, pp.147-57, 2003.
DOI : 10.1046/j.1365-2125.2003.01751.x
, Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients, British Journal of Clinical Pharmacology, vol.23, issue.2, 2003.
DOI : 10.1046/j.0306-5251.2003.01850.x
, A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression*, Clinical Pharmacology & Therapeutics, vol.12, issue.1
DOI : 10.1016/S0009-9236(98)90117-5